Evotec publishes company presentation outlining drug discovery strategy and mid-term value levers

  • Evotec outlined a mid-term plan built around faster-than-market growth, deeper cost cuts, higher monetization at Just Evotec Biologics, asset-pipeline returns.
  • Cost-out program targets more than EUR 60 million in 2025, including Priority Reset impact; D&PD headcount cut by about 600 FTE.
  • Just Evotec Biologics signed a sale of its Toulouse J.POD site to Sandoz, paired with a technology license for J.POD operations.
  • Deal terms include about USD 350 million upfront in 2025, more than USD 300 million in license, milestones, development revenues in 2026-2028.
  • Royalty stream tied to 10 biosimilars from first commercial sale, with six in technical development; milestone and royalty potential cited at over EUR 500 million to 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on July 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.